CancerCare Manitoba
 
 
 
Cancer Prevention Trials


CancerCare Manitoba - Clinical Investigations Office


Breast Cancer Risk Assessment & Prevention Trial

Research Participants Wanted


Image Designed by Freepik

Study Details:

Researchers have found that common genetic variations (called Single Nucleotide Polymorphisms) are associated with a higher risk of developing breast cancer.

This research study offers women free access to a new blood test that looks at your genetic variations to better estimate your personal lifetime risk of developing breast cancer.

Eligible participants will also undergo a standard breast cancer assessment by a CancerCare Manitoba physician with counseling about whether medications to prevent breast cancer would be recommended for you.


Eligibility: Women ages 35-75 with
  • No personal history of breast cancer
  • No prior radiotherapy to the chest
  • No known hereditary breast cancer syndrome (such as BRCA1 or BRCA2)

What to expect if you participate:
  • Learn your lifetime risk of breast cancer
  • Learn what you can do to reduce your risk
  • 1.5 hour commitment
  • No cost to participate

What to do if you are interested in partcipating:

Contact the study coordinator at 204-787-4160 or Email: PreventionStudy@cancercare.mb.ca

Study Sponsors: This study is a joint research endeavour of:





The Clinical Trials Unit (CTU) at Cancer Care Manitoba has been actively involved in conducting cancer prevention trials since 1992. Women in Manitoba are playing a major role in finding ways to reduce the risk of developing breast cancer in high risk women. These women are paving the way for future generations and help to place CCMB at the forefront of research in breast cancer prevention. The three prevention trials we have participated in are outlined below:

BCPT

Breast Cancer Prevention Trial (BCPT) in the 1990's looked at Tamoxifen for preventing breast cancer. Manitoba accrued 140 of the 13,388 women. Study results in April 1998 showed a 49 % reduction in breast cancer among the high risk women who took Tamoxifen.

THE STAR TRIAL

STAR, a Study of Tamoxifen and Raloxifene. Manitoba accrued 139 of the 19,490 women. Results in April 2010 indicated that raloxifene retained 76% of the effectiveness in preventing invasive disease and grew closer to tamoxifen in preventing noninvasive disease, while remaining less toxic. Tamoxifen remains superior to raloxifene in reducing the risk of both invasive and non-invasive breast cancer among postmenopausal women at increased risk.

EXCEL TRIAL

This trial was designed to determine if Exemestane can prevent breast cancer in healthy postmenopausal women at increased risk for developing breast cancer. Manitoba accrued 103 of the 4560 women. Trial results released in June2011 demonstrated a 65 % relative reduction in the incidence of invasive breast cancer compared to the placebo control with no serious toxicity and minimal quality of life differences. This is a significant improvement over Tamoxifen and raloxifene, which had been used for breast cancer prevention. Both reduced breast cancer incidence by about 50% but had significant side effects and therefore had been little used in this preventative role.